Koneksa develops, tests, and validates digital biomarkers to help clients understand the impact of treatments on patients. Koneksa provides remote data collection services and partnerships with technology companies for clinical trials.

Koneksa

Koneksa | 11,049 followers on LinkedIn. Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries. | Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

CEO at Koneksa Health

Chris Benko

Co-founder, Head of Biomarker Exploration at Koneksa Health, Board member at Team Go Get It

Robert Ellis

Stephen Golubieski

Experienced Business Leader at Intersections of Life Sciences, Digital Health, Robotics Technology/Sensors, Law and Ethics

Gary Cohen

Thanks Contract Pharma for covering our recent CBO appointment of Eric Luthi . https://lnkd.in/eXSRT53U

eCOA Consortium Announces a New Article: Implementing Sensor-based Digital Health Technologies in Clinical Trials: Key Considerations from the eCOA Consortium C-Path’s eCOA Consortium is pleased to announce that Implementing Sensor-based Digital Health Technologies in Clinical Trials: Key Considerations from the eCOA Consortium has been published in the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Journal Clinical and Translational Science. The article provides an in-depth assessment of the scientific considerations around the use of sensor-based digital health technologies in clinical trials, all set in the context of supporting trial participant compliance with these technologies. Detailing key topics from clinical considerations to data sharing, the paper represents the collection of eCOA Consortium member experience coupled with peer-reviewed literature and relevant regulatory recommendations. Access here: https://lnkd.in/eZyDKYTW #eCOA #CPath #DHT #DrugDevelopment

Critical Path Institute (C-Path)

We’re thrilled to welcome Eric Luthi as Chief Business Officer. In this newly created role, Mr. Luthi brings over 25 years of experience in life sciences and will lead corporate and business development initiatives at Koneksa. “We’re thrilled to welcome Eric to lead our business development team,” said Chris Benko , CEO and Co-Founder of Koneksa. “With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotal role in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations. His leadership will be invaluable as we empower biopharma companies to utilize digital biomarkers to accelerate clinical trials and unlock critical data insights.” Read the release: https://lnkd.in/eiTKrj2z

For the last four years, Koneksa has proudly committed to promoting civic engagement by observing Election Day as a company holiday. Whether they’re casting a vote or volunteering at the polls, Koneksans are assured the time needed to participate fully in the democratic process. https://lnkd.in/dyCm9XHz #ElectionDay #CivicEngagement #Inclusion #Vote

Last Tuesday our CMO John Wagner, MD, PhD joined jp clancy , Andrew E. M. , Robert Schuck and Nancy M. Allen LaPointe in a lively discussion around Integrating Sensitive Endpoints in Early-Phase Trials at Duke-Margolis Institute for Health Policy ’s workshop around Opportunities to Improve Dose-Finding and Optimization for Rare Disease Drug Development. The discussion included best practices and considerations when selecting appropriate clinical outcome assessments that are also meaningful to patients, with a focus on strategies for integrating sensitive endpoints in early phase trials, including digital measurements. #drugdevelopment #digitalbiomarkers #biomarkers

📢 Register for the upcoming DiMe webinar on October 30, 11am EDT: Regulatory Pathways for Qualification and Acceptance of Digital Health Technology-Derived Clinical Trial Endpoints: Considerations for Sponsors and join Jessie Bakker, MS PhD and Elena Izmailova as they discuss the available regulatory approaches to support the increasing deployment of DHTs within the clinical research setting and to help advance regulatory science in the field of digital medicine, based on the recent publication in American Society for Clinical Pharmacology & Therapeutics ' Journal. Read the article here: https://lnkd.in/eDGy_QBs REGISTER HERE for the webinar👇 https://lnkd.in/eZEPAebt #DiMe #journalclub #DHT #drugdevelopment #Regulatory

🎉🎉 Congratulations to our Chief Medical Officer John Wagner, MD, PhD , for being the recipient of the Gary Neil Prize for Innovation in Drug Development, presented by the American Society for Clinical Pharmacology & Therapeutics which aims to stimulate the application of innovative science to #clinical drug development. 💊💊 John is the latest recipient of this recognition, which was first established in 2004. He joins the ranks of other notable leaders in the industry. Congratulations, John! More info: https://www.ascpt.org/ #ASCPT #innovation #drugdevelopment

📅 Counting down to our next Journal Club on October 30 at 11 a.m. ET! Join us for an engaging discussion featuring the following industry experts: 🗣️ Elena Izmailova ( Koneksa ) 🗣️ Jessie Bakker ( Koneksa ) 🗣️ Benjamin Vandendriessche Digital Medicine Society (DiMe) The session will explore the complexity of obtaining regulatory endorsement for sensor-based digital health technology (sDHT) endpoints in the US. With the lack of approved drugs based on sDHT-derived endpoints, our speakers will review two key regulatory pathways available to pharmaceutical study Sponsors: the traditional IND pathway and the drug development tool (DDT) pathway. We’ll cover the benefits, challenges, and regulatory considerations of each route. 📰 Take a look at the paper we’ll be discussing: https://bit.ly/3NCNLaS 🔗 Register now to secure your spot: https://bit.ly/4e0d6X5

Digital Medicine Society (DiMe)

The work, "Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors", by Jessie Bakker, MS PhD , Elena Izmailova , Aude Clement , Steve Hoffmann , Chris Leptak , Joseph Menetski , and John Wagner, MD, PhD has received over ✨500 views✨ in the Journal of Clinical Pharmacology and Therapeutics since it was published online on August 15, 2024! We are happy to contribute to the advancement of regulatory science and clarify questions around DHT use in drug development. Read our paper here 👇 https://lnkd.in/e6tDKCTt #digitalbiomarkers #DHT #drugdevelopment #clinicaltrials #regulatory #ViewsMilestone ASCPT Journal Family

We are proud to share that our Chief Medical Officer John Wagner, MD, PhD is the American Society for Clinical Pharmacology & Therapeutics 2025 recipient of the prestigious Gary Neil Prize for Innovation in Drug Development, which aims “to stimulate the application of innovative science to clinical drug development.” John is the latest recipient of this recognition, which was first established in 2004. He joins the ranks of other notable leaders in the industry. Congratulations, John! More info: https://www.ascpt.org/ #ASCPT #innovation #drugdevelopment

Metric
Company Name	Koneksa
Symbol
MSH ID	COM:KONEKSAHEALTH
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare Technology
Country	US
Stage	Grant
Employee Count
Website	koneksahealth.com
LinkedIn	koneksa-health
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.31K
Web Traffic Growth	0.35
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

KONE

COM:KONEKSAHEALTH

Koneksa

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue